Parameter Method Sample Type Purpose Significance TAT
1 HLA-B5701 PCR   Blood Confirmation of HLA-B5701   Detects human leukocyte antigen-B (HLA-B) 5701 allele, which is associated with hypersensitivity to the anti-HIV drug abacavir 3 Days
2 IL28B   PCR Blood Confirmation of interleukin 28B (IL28B) Detects a dinucleotide frame-shift variant coding for interleukin 28B (IL28B) and helps to predict the therapeutic response in Hepatitis C Virus infected patients 3 Days
3 Statin-induced myopathy PCR Blood Confirmation of SLCO1B1 c.521   Detects a variant in human solute carrier organic anion transporter family member IBI gene in patients who are at higher risk for developing statin-induced myopathy 3 Days
4 Vitamin K Epoxide Reductase Complex 1 (VKORCI) PCR Blood

Confirmation of KORC1 -1639G

Detects the most important polymorphism in the Vitamin K Epoxide Reductase Complex 1 (VKORCI) gene associated with interindividual dose requirements for oral anticoagulants 3 Days
5 CYP2C9   Multiplex PCR Blood

Confirmation of of CYP2C9 (c.430C>T) and CYP2C9 '3 (c.i 075A>C)

Simultaneous detection of CYP2C9 (c.430C>T) and CYP2C9 '3 (c.i 075A>C) polymorphisms to determine the drug response of coumarin-based anticoagulation therapy 3 Days
6 FCGR PCR-Hybridization Blood

Confirmation of FCGR

Detection of allelic variants of FC gamma-Receptor 2A (HI 31 R) and 3A (Fl 58V) associated with response to IgG antibody therapy 2 Days
7 PGX-5FU PCR-Hybridization Blood

Confirmation of PGX-5FU

Detection of DPYD allelic variant IVSI 4+1 G>A associated with toxicity of 5-FU therapy 2 Days
8 PGX- CYP2C19 PCR-Hybridization Blood

Confirmation of PGX-CYP2C19

Testing for CYP2C19 variants *3, *5, *7, *8 and 7 2 Days
9 PGX - CYP2D6 PCR-Hybridization Blood Confirmation of PGX-CYP2C19 Testing for CYP2D6 variants *3, *4 and *6 2 Days
10 PGX-HIV PCR-Hybridization Blood Confirmation of PGX-HIV Testing for genotypes associated with response to HIV highly active anti-retroviral therapy 2 Days
11 PGX-Thrombo PCR-Hybridization Blood Confirmation CYP2C9 and VKORCI variants Testing for CYP2C9 and VKORCI variants associated with anticoagulant dose requirements 2 Days
12 PGX-TPMT PCR-Hybridization Blood Confirmation of TPMT variants *2, *3A, *3B and *3C Testing for TPMT variants *2, *3A, *3B and *3C associated with response to thiopurine therapy 2 Days

Contact

Rajiv Gandhi Centre for Biotechnology (RGCB),
Thycaud Post, Poojappura,
Thiruvananthapuram - 695 014, Kerala, India
+91-471-2529400 | 2347975 | 2348753
+91-471-2348096
webmaster@rgcb.res.in

My Gov www.mygov.in Prime Ministers National Relife Fund India Gov www.india.gov.in Make In India www.makeinindia.gov.in Make In India www.iredibleindia.org Data gov in www.data.gov.in www.pib.gov.in

Last Updated on: September 22, 2020
CERT-In Certified Website